Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer
Authors:
- Harshabad SinghHSHarshabad Singh
- Rachel B. KellerRKRachel B. Keller
- Kevin S. KapnerKKKevin S. Kapner
- Julien DillyJDJulien Dilly
- Srivatsan RaghavanSRSrivatsan Raghavan
- Chen YuanCYChen Yuan
- Elizabeth F. CohenECElizabeth F. Cohen
- Michael TolstorukovMTMichael Tolstorukov
- Elizabeth AndrewsEAElizabeth Andrews
- Lauren K. BraisLBLauren K. Brais
- Annacarolina da SilvaASAnnacarolina da Silva
- Kimberly PerezKPKimberly Perez
- 18 July 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (22) , 4627-4643
Abstract
Purpose: Approximately 8% to 10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. Experimental Design: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multigene sequencing panel and identified 73 patients (9.2%) with KRAS wild-type (WT) pancreatic cancer. Results: Overall, 43.8% (32/73) of KRAS WT cases had evidence of an alternative driver of the MAPK pathway, including BRAF mutations and in-frame deletions and receptor tyrosine kinase fusions. Conversely, 56.2% of cases did not harbor a clear MAPK driver alteration, but 29.3% of these MAPK-negative KRAS WT cases (12/41) demonstrated activating alterations in other oncogenic drivers, such as GNAS, MYC, PIK3CA, and CTNNB1. We demonstrate potent efficacy of pan-RAF and MEK inhibition in patient-derived organoid models carrying BRAF in-frame deletions. Moreover, we demonstrate durable clinical benefit of targeted therapy in a patient harboring a KRAS WT tumor with a ROS1 fusion. Clinically, patients with KRAS WT tumors were significantly younger in age of onset (median age: 62.6 vs. 65.7 years; P = 0.037). SMAD4 mutations were associated with a particularly poor prognosis in KRAS WT cases. Conclusions: This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials. See related commentary by Kato et al., p. 4527Keywords
All Related Versions
Funding Information
- National Cancer Institute (CA218420-02)
- National Cancer Institute (P50CA127003)
- Lustgarten Foundation (na)
- Doris Duke Charitable Foundation (na)
This publication has 57 references indexed in Scilit:
- Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120Cancer Discovery, 2016
- Whole genomes redefine the mutational landscape of pancreatic cancerNature, 2015
- Cabozantinib Overcomes Crizotinib Resistance in ROS1 Fusion–Positive CancerClinical Cancer Research, 2015
- The landscape and therapeutic relevance of cancer-associated transcript fusionsOncogene, 2014
- Anchored multiplex PCR for targeted next-generation sequencingNature Medicine, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Clinicopathological Correlates of Activating GNAS Mutations in Intraductal Papillary Mucinous Neoplasm (IPMN) of the PancreasAnnals of Surgical Oncology, 2013
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancerGenes & Development, 2006